Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Cardiovascular Outcomes in ESRD Haemodialysis
NCT04764097Phase 3Withdrawn
- Sponsor
- Tan Tock Seng Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dapagliflozin in end stage renal disease (ESRD), sponsored by Tan Tock Seng Hospital. Planned start Jun 2021; status: withdrawn.
02
Drugs
dapagliflozin
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT04764097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764097.